G0F Stock Overview
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.74 |
| 52 Week High | €7.40 |
| 52 Week Low | €3.24 |
| Beta | 0.67 |
| 1 Month Change | 16.75% |
| 3 Month Change | -9.71% |
| 1 Year Change | -14.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -37.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| G0F | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.8% | 0.6% | -0.5% |
| 1Y | -14.6% | -25.7% | 4.3% |
Return vs Industry: G0F exceeded the German Biotechs industry which returned -25.5% over the past year.
Return vs Market: G0F underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| G0F volatility | |
|---|---|
| G0F Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: G0F's share price has been volatile over the past 3 months.
Volatility Over Time: G0F's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 23,000 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
| G0F fundamental statistics | |
|---|---|
| Market cap | €5.92b |
| Earnings (TTM) | €189.00m |
| Revenue (TTM) | €6.66b |
35.5x
P/E Ratio1.0x
P/S RatioIs G0F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G0F income statement (TTM) | |
|---|---|
| Revenue | €6.66b |
| Cost of Revenue | €4.09b |
| Gross Profit | €2.56b |
| Other Expenses | €2.37b |
| Earnings | €189.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 38.51% |
| Net Profit Margin | 2.84% |
| Debt/Equity Ratio | 140.3% |
How did G0F perform over the long term?
See historical performance and comparison